2025-10-04 - Analysis Report
Okay, here's an analysis of Eli Lilly (LLY) based on the provided information, formatted as a report.

**Report: Eli Lilly (LLY) Stock Analysis**

**1. Performance Overview**

*   **Ticker:** LLY (Eli Lilly and Co)
*   **Company Description:** Eli Lilly is a global pharmaceutical company that develops and markets medicines across various therapeutic areas.

**1.1. Return vs. S&P 500 (VOO)**

*   **LLY Cumulative Return:** 222.30%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Spread (LLY - VOO):** 123.79%
*   **Spread Range:** (Max: 248.5, Min: -33.6)
*   **Current Spread:** 115.4
*   **Relative Spread:** 52.8

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO).  The current spread, 115.4, indicates substantial outperformance. A relative spread of 52.8 suggests the current outperformance is positioned in the mid-range of its historical spread.

**1.2. Alpha, Beta Analysis**

| Year       | CAGR    | MDD      | Alpha  | Beta  | Cap(B) |
|------------|---------|----------|--------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%    | -17.0% | -0.0  | 75.7   |
| 2016-2018  | 39.0%   | 68.9%    | 24.0%  | -0.0  | 103.7  |
| 2017-2019  | 41.0%   | 68.9%    | 19.0%  | 0.4   | 117.8  |
| 2018-2020  | 34.0%   | 79.8%    | 10.0%  | 0.4   | 151.4  |
| 2019-2021  | 53.0%   | 79.8%    | 7.0%   | 0.5   | 247.6  |
| 2020-2022  | 64.0%   | 79.8%    | 65.0%  | 0.4   | 328.0  |
| 2021-2023  | 125.0%  | 78.9%    | 124.0% | 0.2   | 522.6  |
| 2022-2024  | 134.0%  | 81.2%    | 113.0% | 0.2   | 692.1  |
| 2023-2025  | 114.0%  | 83.5%    | 51.0%  | 0.2   | 752.9  |

**Analysis:**

*   **CAGR:**  LLY has demonstrated strong Compound Annual Growth Rate (CAGR) over various periods, especially in recent years.
*   **MDD:** Maximum Drawdown (MDD) is high, indicating significant volatility.
*   **Alpha:**  LLY shows consistently positive Alpha, particularly in recent periods, indicating significant outperformance relative to its benchmark.
*   **Beta:**  Beta is relatively low, suggesting that LLY's price is less sensitive to market movements than the S&P 500.
*   **Market Cap:**  LLY's market capitalization has grown substantially, reflecting its growth and investor confidence.

**2. Recent Price Action**

*   **Current Price:** 839.87
*   **Previous Close:** 819.85
*   **Change:** 2.44%
*   **5-Day Moving Average:** 795.164
*   **20-Day Moving Average:** 759.9295
*   **60-Day Moving Average:** 744.0788

**Analysis:**  LLY is trading above its 5, 20, and 60-day moving averages, indicating a short-term, mid-term, and long-term upward trend.  The 2.44% change since the previous close suggests a recent positive price surge.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 71.36 (Approaching overbought territory)
*   **PPO:** 1.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Delta_Previous_Relative_Divergence:** 12.8 (+) (Short-term increase in relative divergence)
*   **Expected Return:** 119.3% (Long-term, S&P 500-relative)

**Analysis:**

*   The MRI suggests LLY is considered a good investment currently.
*   RSI is above 70, suggesting the stock may be overbought in the short term.
*   The positive change in relative divergence reinforces the recent positive price momentum.
*   The high expected return (119.3%) signals significant potential for long-term outperformance compared to the S&P 500.
*   The Hybrid Signal recommends a fully invested position, emphasizing its perceived safety.
*   The 2.44% price increase since the previous close suggests a significant event likely drove the price higher.

**4. Recent News & Significant Events**

*   **[2025-10-03] Eli Lilly (LLY) Laps the Stock Market: Here's Why (Zacks)**
*   **[2025-10-03] US Equity Indexes Rise This Week as AI-Trade Lifts Tech, Healthcare Gains Following Pfizer Deal (MT Newswires)**
*   **[2025-10-03] 5 Large Cap Drug Stocks: Values or Traps? (Zacks)**
*   **[2025-10-03] Palantir, AI bubble comments, pharma stocks: Trending Tickers (Yahoo Finance Video)**
*   **[2025-10-03] Why Shares of Eli Lilly Soared This Week (Motley Fool)**
*   **[2025-10-03] MRK Stock Up Nearly 14% So Far This Week: What's Driving It? (Zacks)**

**Analysis:** Recent news indicates positive sentiment towards LLY, highlighting its strong performance relative to the market and potential growth drivers.  The Motley Fool article, "Why Shares of Eli Lilly Soared This Week," is particularly relevant in understanding the recent price surge. The healthcare sector and potential AI applications seem to be contributing factors.

**4.2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.79 (~Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 884.48 / 1190.00 / 650.00

**Analysis:**  The analyst consensus is a "Buy," with a mean rating suggesting strong confidence. The average target price of $884.48 indicates potential upside from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출         |
|------------|-------|--------------|
| 2025-08-07 | 6.3   | 15.56 B$     |
| 2025-05-01 | 3.07  | 12.73 B$     |
| 2024-10-30 | 1.08  | 11.44 B$     |
| 2024-08-08 | 3.29  | 11.30 B$     |
| 2025-08-07 | 3.29  | 11.30 B$     |

**Analysis:**  Recent earnings data shows a significant increase in both EPS and revenue, especially in the most recent quarter (2025-08-07). This growth likely contributes to positive investor sentiment.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | $18.27B   | 30.98%    |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |
| 2024-06-30   | $13.56B   | 21.88%    |

**Analysis:**  LLY demonstrates strong revenue growth and exceptional profit margins.  Return on Equity (ROE) is also high, indicating efficient use of shareholder equity to generate profits.

**7. Overall Summary and Conclusion**

Eli Lilly (LLY) presents a compelling investment case based on the provided data.  It has significantly outperformed the S&P 500, demonstrates strong financial performance with growing revenue, high profit margins, and a robust ROE.  Analysts have a positive outlook with a "Buy" consensus and potential upside to the target price.  Technical indicators are generally favorable, though the RSI suggests caution in the short term due to potential overbought conditions. Recent news highlights positive market sentiment and specific drivers for recent price increases. The high expected return signals continued outperformance in the long term. Therefore, it is advisable to buy LLY.
